OctoPlus N.V. : OctoPlus Announces Delisting of Shares
Leiden, the Netherlands, 15 March 2013 - OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO), announces that, following the acquisition of
98.6% of all issued and outstanding ordinary shares in the Company (the
"Shares") by Reddy Netherlands B.V., a fully-owned subsidiary of Dr. Reddy's
Laboratories Ltd., delisting of the Shares was approved by NYSE Euronext
Amsterdam. The delisting of the Shares will take effect on 16 April 2013. The
last trading day will be 15 April 2013.
The Company is reminding shareholders that following delisting shareholders
will no longer be able to trade the Shares via the NYSE Euronext Amsterdam
stock exchange in the usual way. Furthermore, it remains uncertain if, to what
extent, under which conditions and at what cost processing of the Shares in
the Euroclear giro system may be continued after delisting.
This is a press release by OctoPlus N.V. pursuant to the provision of Article
5:25i of the Dutch Act on the Financial Supervision (Wet op het financieel
OctoPlus is a leading European provider of advanced drug formulation and
clinical scale manufacturing services to the pharmaceutical and biotechnology
industries, with a focus on difficult to formulate active pharmaceutical
ingredients. OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under
the symbol OCTO. For more information about OctoPlus, please visit our website
In addition, OctoPlus is a specialty pharmaceutical company focused on the
development and manufacture of improved injectable pharmaceuticals based on
our proprietary drug delivery technologies that exhibit fewer side effects,
improved patient convenience and a better efficacy/safety balance than
existing therapies. OctoPlus also focuses on the development of long-acting,
controlled release versions of known protein therapeutics, peptides and small
molecules, including specialty generics.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an
English version and a Dutch version of this document, the English version will
prevail over the Dutch version.
Click here for the press release in PDF
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.